CVAC Key Statistics, Chart & Performance
The current stock price of CVAC is 4.66 USD. In the past month the price decreased by -8.98%. In the past year, price increased by 10.69%.
CVAC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About CVAC
Company Profile
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Company Info
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG 72076 DE
CEO: Franz-Werner Haas
Employees: 825
Phone: 49707198830
CUREVAC NV / CVAC FAQ
Can you describe the business of CUREVAC NV?
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Can you provide the latest stock price for CUREVAC NV?
The current stock price of CVAC is 4.66 USD. The price decreased by -0.21% in the last trading session.
Does CUREVAC NV pay dividends?
CVAC does not pay a dividend.
What is the ChartMill technical and fundamental rating of CVAC stock?
CVAC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for CVAC stock?
11 analysts have analysed CVAC and the average price target is 4.78 USD. This implies a price increase of 2.53% is expected in the next year compared to the current price of 4.66.
What is the expected growth for CVAC stock?
The Revenue of CUREVAC NV (CVAC) is expected to decline by -84.14% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
CVAC Technical Analysis
CVAC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CVAC. Both the profitability and the financial health of CVAC get a neutral evaluation. Nothing too spectacular is happening here.
CVAC Financial Highlights
Over the last trailing twelve months CVAC reported a non-GAAP Earnings per Share(EPS) of 0.68. The EPS increased by 20.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 182.11% | ||
| ROA | 11.31% | ||
| ROE | 14.79% | ||
| Debt/Equity | 0.03 |
CVAC Forecast & Estimates
11 analysts have analysed CVAC and the average price target is 4.78 USD. This implies a price increase of 2.53% is expected in the next year compared to the current price of 4.66.
For the next year, analysts expect an EPS growth of -163.99% and a revenue growth -84.14% for CVAC